abrdn Life Sciences Investors $HQL Shares Newly Purchased by City of London Investment Management Co. Ltd.

Key Points

• City of London Investment Management opened a new position in abrdn Life Sciences Investors, buying 72,865 shares worth about $1.36 million, or roughly 0.24% of the fund.
• Other institutional investors also increased holdings, and institutions collectively owned 32.21% of HQL’s shares.
• HQL recently paid a quarterly dividend of $0.62 per share, equivalent to a 13.5% annualized yield based on the article’s figures.

City of London Investment Management Co. Ltd. purchased a new position in abrdn Life Sciences Investors (NYSE:HQL - Free Report) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 72,865 shares of the company's stock, valued at approximately $1,363,000. City of London Investment Management Co. Ltd. owned approximately 0.24% of abrdn Life Sciences Investors as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HQL. Flagship Harbor Advisors LLC increased its holdings in shares of abrdn Life Sciences Investors by 4.1% in the 3rd quarter. Flagship Harbor Advisors LLC now owns 417,366 shares of the company's stock valued at $7,805,000 after acquiring an additional 16,601 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in abrdn Life Sciences Investors by 57.3% in the first quarter. Allspring Global Investments Holdings LLC now owns 362,535 shares of the company's stock worth $5,898,000 after purchasing an additional 132,098 shares during the period. 180 Wealth Advisors LLC boosted its holdings in abrdn Life Sciences Investors by 2.2% in the second quarter. 180 Wealth Advisors LLC now owns 152,829 shares of the company's stock worth $3,058,000 after purchasing an additional 3,271 shares during the period. Blue Bell Private Wealth Management LLC increased its stake in abrdn Life Sciences Investors by 13.7% during the third quarter. Blue Bell Private Wealth Management LLC now owns 105,642 shares of the company's stock valued at $1,976,000 after purchasing an additional 12,743 shares during the last quarter. Finally, Royal Bank of Canada increased its stake in abrdn Life Sciences Investors by 16.5% during the first quarter. Royal Bank of Canada now owns 121,240 shares of the company's stock valued at $1,972,000 after purchasing an additional 17,152 shares during the last quarter. 32.21% of the stock is owned by institutional investors.

abrdn Life Sciences Investors Price Performance

Shares of NYSE:HQL opened at $18.35 on Thursday. abrdn Life Sciences Investors has a 1-year low of $15.66 and a 1-year high of $22.67. The company's fifty day moving average is $18.87 and its two-hundred day moving average is $18.25.

abrdn Life Sciences Investors Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Monday, August 24th were issued a dividend of $0.62 per share. The ex-dividend date of this dividend was Monday, August 24th. This represents a $2.48 annualized dividend and a dividend yield of 13.5%.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors is a publicly traded closed-end investment company listed on the New York Stock Exchange under the symbol HQL. The fund seeks long-term capital appreciation by investing in companies involved in the life sciences industry.

Its portfolio may include businesses across biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services and related fields. The fund can invest in both publicly traded and privately held companies, providing shareholders with diversified exposure to innovative healthcare and life sciences businesses.

The fund was formerly known as Tekla Life Sciences Investors and adopted the abrdn name following the integration of Tekla's investment management activities into abrdn.

Want to see what other hedge funds are holding HQL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for abrdn Life Sciences Investors (NYSE:HQL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.